News | August 06, 2024
OneSource and BRL ink technology licensing agreement to deliver high-concentration biologics subcutaneously
Revolutionary technology will further boost OneSource’s scientific services offerings
Revolutionary technology will further boost OneSource’s scientific services offerings
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Renews GMP certifications for India and Malaysia sites
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies,
The state-of-the-art facility is equipped with best-in-class equipment and control systems
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Subscribe To Our Newsletter & Stay Updated
